Möchten Sie immer auf dem neuesten Stand bleiben?

New Delhi, April 23, 2024 (GLOBE NEWSWIRE) -- The global ultrasound devices market is projected to reach US$ 11,229.9 million by 2032, up from US$ 7,402.2 million in 2023, at a CAGR of 4.74% during...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Pyzchiva® approved as one of first ustekinumab biosimilars in EuropeEC approval based on robust development program...

NEW YORK, April 20, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...

NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...

NEW YORK, April 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...

Visiongain has published a new report entitled Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034: Forecasts by Indication (Crohn's Disease, Ulcerative Colitis), by Route of...

– PALI-2108 in development for the treatment of moderate-to-severe ulcerative colitis (UC) advancing towards Phase 1 clinical study before year end Carlsbad, CA, April 10, 2024 (GLOBE...

Chicago, April 09, 2024 (GLOBE NEWSWIRE) -- Monoclonal Antibody (mABs) Therapeutics market in terms of revenue was estimated to be worth $252.6 billion in 2024 and is poised to reach $497.5 billion...

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...

Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "Global Irritable Bowel Disease Market (2024 Edition): Analysis By Drug Class (Corticosteroids, JAK inhibitors, TNF inhibitors, Other Drug Classes), By...